DiscoverPeerVoice Oncology & Haematology VideoPeter Schmid, FRCP, MD, PhD - Staying at the Forefront of HER2 and TROP2-Directed Antibody-Drug Conjugate Advances in Breast Cancer
Peter Schmid, FRCP, MD, PhD - Staying at the Forefront of HER2 and TROP2-Directed Antibody-Drug Conjugate Advances in Breast Cancer

Peter Schmid, FRCP, MD, PhD - Staying at the Forefront of HER2 and TROP2-Directed Antibody-Drug Conjugate Advances in Breast Cancer

Update: 2024-10-11
Share

Description

Visit https://www.peervoice.com/QWV860 to view the entire programme with slides. After completing “Peter Schmid, FRCP, MD, PhD - Staying at the Forefront of HER2 and TROP2-Directed Antibody-Drug Conjugate Advances in Breast Cancer”, participants will be able to: Describe antibody-drug conjugates (ADC)-based combination strategies that are in clinical development for HER2-positive metastatic breast cancer; Evaluate emerging updates on ADCs for the treatment of HER2-positive metastatic breast cancer; Assess therapeutic advances in hormone-receptor-positive metastatic breast cancer based on HER2 status in the context of current treatment guidelines; and Identify emerging ADC-based strategies being explored for high-risk HER2-positive early breast cancer.
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Peter Schmid, FRCP, MD, PhD - Staying at the Forefront of HER2 and TROP2-Directed Antibody-Drug Conjugate Advances in Breast Cancer

Peter Schmid, FRCP, MD, PhD - Staying at the Forefront of HER2 and TROP2-Directed Antibody-Drug Conjugate Advances in Breast Cancer

PeerVoice